News >

NICE Recommends Lenalidomide/Rituximab for Follicular Lymphoma

Gina Columbus @ginacolumbusonc
Published: Thursday, Feb 27, 2020

Meindert Boysen, PharmD

Meindert Boysen, PharmD

The United Kingdom’s National Institute for Health and Care Excellence (NICE) has recommended the combination of lenalidomide (Revlimid) and rituximab (Rituxan; R2) as a treatment option for adult patients with grade 1 to 3A previously treated follicular lymphoma.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication